Squalamine can improve the treatment of Parkinson's disease

Scientists report that a compound which occurrs naturally blocks the molecular processes of Parkinson's disease and inhibits its toxic products. The study was completed using recombinant rat proteins by the University of Cambridge and the United States National Institutes of Health and other academic centers in Europe and America.

In the new study, the researchers conducted a series of experiments on the interaction between squalamine, α-synuclein and lipid vesicles. They found that squalamine inhibits protein aggregation by competing for binding sites on the surface of vesicles. By displacing the protein in this manner, it significantly reduces the rate of toxic particle formation. Further tests conducted in human nerve cells show that squalamine inhibits the toxicity of these particles.

Finally, the team tested the effect of squalamine in animal models of Parkinson's disease and used nematodes to express the α-synuclein gene in muscle cells. When the nematode develops, the α-synuclein gene prevents them from moving and the ingestion of salicylamine from the mouth can prevent such paralysis. All the results show that squalamine can be used as a basis for at least some of the symptoms of Parkinson's disease. Researchers said they are planning to conduct clinical trials on Parkinson's patients in the United States.

However, there are further studies to be confirmed, such as the exact benefits of squalamine and drugs may lead to any results. In particular, it is unclear whether squalamine can reach the brain-specific regions of the major molecular processes responsible for Parkinson's disease.

The researchers believe that the initiation of the investigation of salmianol to relieve other symptoms of the effect will be very interesting. By targeting the gastrointestinal system and influencing α-synuclein in the gut, the compound may alleviate severe constipation experienced by the patient. So this treatment can lead to other parts of the body cascade signal, at least in the peripheral nervous system relieve Parkinson's disease. Parkinson's disease has many symptoms. The researchers hope that this compound or its derivatives have a similar mechanism of action to alleviate some of these symptoms and to improve the patient's life at least. Flarebio offers high-quality recombinant proteins like recombinant TLR2 at good prices.